Condition: Hormone-refractory Prostate Cancer · Sponsor: Vir Biotechnology, Inc.
The study will be conducted in 4 parts and will commence with dose escalation of VIR-5500 as a monotherapy (Part 1), followed by combination escalation (Part 3a), monotherapy dose expansion (Part 2) and combination dose expansion (Part 4a). * Part 1 (Monotherapy Dose Escalation): Single-agent VIR-5500 dose escalation * Part 2 (Monotherapy Dose Expansion): Single-agent VIR-5500 dose expansion * Part 3 (Combination Dose Escalation): VIR-5500 plus another therapeutic agent dose escalation Part 3a (Combination Dose Escalation): VIR-5500 in combination with an androgen receptor signaling inhibitor (ARSI) * Part 4 (Combination Dose Expansion): VIR-5500 plus another therapeutic agent dose expansion Part 4a (Combination Dose Expansion): VIR-5500 in combination with an androgen receptor signaling inhibitor (ARSI)
This description comes directly from the study's public registry record.
Study Inquiry · 415-654-5281 · clinicaltrials@vir.bio
Always discuss trial participation with your own doctor first.
| Investigational Site Number: 403 | Palo Alto, California, United States | Recruiting |
| Investigational Site Number: 401 | Houston, Texas, United States | Recruiting |
| Investigational Site number: 404 | Fairfax, Virginia, United States | Recruiting |
| Investigational Site Number: 400 | Seattle, Washington, United States | Recruiting |
| Investigational Site Number: 100 | Melbourne, Australia | Recruiting |
| Investigational Site Number: 101 | Sydney, Australia | Recruiting |
| Investigational Site Number: 251 | Barcelona, Spain | Withdrawn |
| Investigational Site Number: 250 | Barcelona, Spain | Recruiting |
| Investigational Site Number: 254 | Madrid, Spain | Recruiting |
| Investigational Site Number: 252 | Madrid, Spain | Recruiting |
| Investigational Site Number: 253 | Pamplona, Spain | Recruiting |
| Investigational Site Number: 300 | London, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05997615